- Home
- CSTL vs ARVN Comparison
CSTL vs ARVN Comparison
Compare CSTL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- ARVN
- Stock Information
- Founded
- CSTL 2007
- ARVN 2015
- Country
- CSTL United States
- ARVN United States
- Employees
- CSTL N/A
- ARVN N/A
- Industry
- CSTL Medical Specialities
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CSTL Health Care
- ARVN Health Care
- Exchange
- CSTL Nasdaq
- ARVN Nasdaq
- Market Cap
- CSTL 471.5M
- ARVN 456.2M
- IPO Year
- CSTL 2019
- ARVN 2018
- Fundamental
- Price
- CSTL $19.36
- ARVN $6.29
- Analyst Decision
- CSTL Strong Buy
- ARVN Buy
- Analyst Count
- CSTL 6
- ARVN 22
- Target Price
- CSTL $37.67
- ARVN $20.21
- AVG Volume (30 Days)
- CSTL 554.7K
- ARVN 2.1M
- Earning Date
- CSTL 08-04-2025
- ARVN 08-06-2025
- Dividend Yield
- CSTL N/A
- ARVN N/A
- EPS Growth
- CSTL N/A
- ARVN N/A
- EPS
- CSTL N/A
- ARVN N/A
- Revenue
- CSTL $346,269,000.00
- ARVN $372,800,000.00
- Revenue This Year
- CSTL N/A
- ARVN $7.57
- Revenue Next Year
- CSTL $1.62
- ARVN N/A
- P/E Ratio
- CSTL N/A
- ARVN N/A
- Revenue Growth
- CSTL 20.40
- ARVN 299.57
- 52 Week Low
- CSTL $14.59
- ARVN $5.90
- 52 Week High
- CSTL $35.84
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- CSTL 58.66
- ARVN 30.61
- Support Level
- CSTL $18.81
- ARVN $6.06
- Resistance Level
- CSTL $21.33
- ARVN $7.83
- Average True Range (ATR)
- CSTL 0.92
- ARVN 0.40
- MACD
- CSTL 0.45
- ARVN -0.16
- Stochastic Oscillator
- CSTL 70.74
- ARVN 11.00
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.